Tetrahydropyridoindole derivatives
View Patent ↗The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.
1. The compound of Formula I,
wherein
R 1 , R 2 , R 3 and R 4 independently represent hydrogen, C 1 -C 5 -alkyl, C 1 -C 5 -alkoxy, halogen, nitro, cyano or formyl; and
R 5 represents phenyl-carbonyl or naphthyl-carbonyl, wherein the phenyl or naphthyl moiety is optionally substituted by one or more substituents selected from C 1 -C 5 -alkyl, C 1 -C 5 -alkoxy and halogen;
or a salt of the compound.
2. The compound according to claim 1 , wherein R 2 is selected from methyl, fluoro, chloro, bromo and trifluoromethyl; R 3 is hydrogen or chloro; and R 1 and R 4 are both hydrogen;
or a salt of the compound.
3. The compound according to claim 1 , wherein R 5 represents naphthyl-carbonyl, wherein the naphthyl moiety is unsubstituted or substituted by one or more substituents selected from C 1 -C 5 -alkyl, C 1 -C 5 -alkoxy and halogen;
or a salt of the compound.
4. The compound according to claim 1 , wherein R 5 represents naphthyl-carbonyl, wherein the naphthyl moiety is unsubstituted or substituted by one or two substituents selected from C 1 -C 5 -alkyl, C 1 -C 5 -alkoxy and halogen;
or a salt of the compound.
5. The compound according to claim 4 , wherein said naphthyl-carbonyl is naphthalene-1-carbonyl;
or a salt of the compound.
6. The compound according to claim 4 , wherein said substituents are selected from C 1 -C 5 -alkoxy and halogen;
or a salt of the compound.
7. The compound according claim 4 , wherein said substituents are selected from methoxy, ethoxy, and fluoro;
or a salt of the compound.
8. The compound according to claim 1 , wherein R 5 represents phenyl-carbonyl, wherein the phenyl moiety is unsubstituted or substituted by one or two substituents selected from C 1 -C 5 -alkyl, C 1 -C 5 -alkoxy and halogen;
or a salt of the compound.
9. The compound according to claim 8 , wherein said substituents are selected from C 1 -C 5 -alkyl and halogen;
or a salt of the compound.
10. The compound according claim 8 , wherein said substituents are selected from methyl, fluoro, chloro and bromo;
or a salt of the compound.
11. The compound according claim 1 , wherein the compound is [8-fluoro-2-(2-methoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid, or a salt of the compound.
12. The compound according claim 1 , wherein the compound is [8-chloro-2-(4-methoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid, or a salt of the compound.
13. The compound according claim 1 , wherein the compound is [8-methyl-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid, or a salt of the compound.
14. The compound according claim 1 , wherein the compound is [8-fluoro-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid, or a salt of the compound.
15. The compound according claim 1 , wherein the compound is [8-chloro-2-(2-ethoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid, or a salt of the compound.
16. The compound according claim 1 , wherein the compound is [2-(4-fluoro-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid, or a salt of the compound.
17. The compound according claim 1 , wherein the compound is [2-(3-chloro-benzoyl)-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid, or a salt of the compound.
18. The compound according claim 1 , wherein the compound is [2-(3-chloro-benzoyl)-8-fluoro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid, or a salt of the compound.
19. The compound according to claim 1 , wherein R 1 , R 2 , R 3 and R 4 represent hydrogen;
or a salt of the compound.
20. The compound according to claim 1 , wherein one or two substituents selected from R 1 , R 2 , R 3 and R 4 independently represent methyl, trifluoromethyl, methoxy, fluoro, chloro or bromo;
or a salt of the compound.
21. The compound according to claim 1 , wherein the compound is:
(2-benzoyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
[2-(3,4,5-trimethoxy-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(4-methoxy-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-methoxy-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(4-tert.-butyl-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(4-chloro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(3,5-dimethoxy-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(3-chloro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b)] indol-5-yl]-acetic acid;
[2-(4-bromo-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
(2-benzoyl-8-methoxy-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-7-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-8-bromo-1,2,3,4-tetrahydro-pyrido[4,3-b)]indol-5-yl)-acetic acid;
(2-benzoyl-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-6-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
[2-(2-bromo-3-methyl-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-bromo-5-methyl-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid; or
[2-(2-ethoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid
or a salt of the compound.
22. The compound according to claim 1 , wherein the compound is:
[7-chloro-2-(3-chloro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-chloro-2-(3-chloro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[6-chloro-2-(3-chloro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(3-chloro-benzoyl)-7-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(3-chloro-benzoyl)-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-fluoro-2-(2-methoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-fluoro-2-(4-methoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-chloro-2-(2-methoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-chloro-2-(4-methoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-methoxy-naphthalene-1-carbonyl)-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(4-methoxy-naphthalene-1-carbonyl)-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
2-(2-methoxy-naphthalene-1-carbonyl)-7-methyl-1,2,3,4-tetrahydro-pyrido[4,3-bit indol-5-yl]-acetic acid;
[2-(2-ethoxy-naphthalene-1-carbonyl)-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-ethoxy-naphthalene-1-carbonyl)-7-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(4-methoxy-naphthalene-1-carbonyl)-7-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-fluoro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(3-fluoro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(3,5-difluoro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b)]indol-5-yl]-acetic acid;
[2-(3,4,5-trifluoro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2,3,4,5-tetrafluoro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b)] indol-5-yl]-acetic acid;
(2-benzoyl-8-fluoro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-6-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b)]indol-5-yl)-acetic acid;
(2-benzoyl-8-isopropyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-7,8-dichloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-8-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-8-tert-butyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-7-chloro-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b)]indol-5-yl)-acetic acid;
(2-benzoyl-7,8-dimethyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
(2-benzoyl-7-fluoro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl)-acetic acid;
[8-chloro-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[6-chloro-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[7-methyl-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-methyl-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-bromo-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-fluoro-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-bromo-3-methyl-benzoyl)-7-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-bromo-3-methyl-benzoyl)-8-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b)]indol-5-yl]-acetic acid;
[2-(2-bromo-3-methyl-benzoyl)-6-chloro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-bromo-3-methyl-benzoyl)-7-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-bromo-3-methyl-benzoyl)-8-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-bromo-2-(2-bromo-3-methyl-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-bromo-3-methyl-benzoyl)-8-fluoro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-bromo-2-(2-ethoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-ethoxy-naphthalene-1-carbonyl)-8-fluoro-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[8-chloro-2-(2-ethoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(4-methoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(5-bromo-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(4-methyl-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-methyl-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(4-fluoro-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid;
[2-(2-methoxy-naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid; or
[2-(2,4,6-trifluoro-benzoyl)-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-yl]-acetic acid
or a salt of the compound.
23. A pharmaceutical composition comprising at least one compound according to any one of claims 21 , 22 , 1 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , or 18 , or a salt of the compound, and an inert carrier material and/or adjuvant.
24. A method of antagonizing prostaglandin D2 mediated hCRTH2 receptor activity, comprising administering to a subject in need thereof an effective amount of the compound according to any one of claims 21 , 22 , 1 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , or 18 , or a salt of the compound.
25. The method of claim 24 , wherein the subject suffers from allergic asthma, rhinitis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, anaphylactic shock, urticaria, eczema, itching, Churg-Strauss syndrome, or sinusitis.